Catalent Pharma Solutions has teamed up with South Korea's CTC Bio to attract clients looking to market solid oral dose and controlled-release products in the U.S. and Europe.
Pfizer has launched a joint venture with China's Zhejiang Hisun Pharmaceuticals, a contract API manufacturer, planning to develop, manufacture and commercialize off-patent pharmaceutical products in China.
Global CMO Patheon reported a 115% increase in gross profit in its fiscal third quarter, after suffering a $20.9 million quarterly operating loss in March.
Global CMO Patheon sold its secondary clinical packaging and clinical distribution services business, part of the company's ongoing efforts to slash costs and reposition itself.
The FDA found sterility issues at DPT Laboratories' Center of Excellence for Sterile and Specialty Products, and the agency said DPT hasn't done enough to prevent future problems.
Looking to cut costs, Hospira is practicing some vertical integration, spending $200 million on an Indian API-producing plant run by Orchid Chemicals & Pharmaceuticals.
Charles River Labs spent $17 million to acquire Accugenix, a provider of contract microbial testing, looking to bolster its own detection portfolio.
During a conference call with analysts last year, United Drug's CEO disclosed that Catalent was selling its packaging business. Fast-forward a year later and Catalent has filed a lawsuit, saying the disclosure was a breach of confidentiality.
Despite its plans to move away from contract manufacturing and boost its proprietary products, West Pharmaceutical is building an injectables plant in Sri City, India.
Just as India's Claris Lifesciences got out from under a two-year FDA ban, Pfizer ($PFE) nixed its supply deal with the company and will no longer sell generic injectables manufactured by the drugmaker.